Moreover, our findings come in agreement with those reported in two previous studies: the first one identified pathogenic mutations in ATM, CHEK2, and PALB2 genes [50], and the second one identified pathogenic mutations in the ATM, PALB2, CHEK2, MSH2, MSH6, and MUTYH genes in Chinese patients with familial breast/ovarian cancer [48]. This evidence concerns the gene MUTYH and Hereditary breast and ovarian cancer syndrome.